Indrayani Biotech Limited (BOM:526445)
17.64
-0.36 (-2.00%)
At close: May 6, 2025
Indrayani Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 5.82 | 30.37 | 15.03 | 6.79 | 14.02 | Upgrade
|
Short-Term Investments | 296.7 | 96.58 | 6.77 | - | - | Upgrade
|
Cash & Short-Term Investments | 302.52 | 126.94 | 21.8 | 6.79 | 14.02 | Upgrade
|
Cash Growth | 138.31% | 482.33% | 221.19% | -51.59% | - | Upgrade
|
Accounts Receivable | 395.29 | 299.72 | 140.99 | 47.68 | 70.45 | Upgrade
|
Other Receivables | 245.41 | 177.15 | 12.83 | 14.57 | - | Upgrade
|
Receivables | 709.17 | 500.53 | 153.82 | 62.25 | 70.45 | Upgrade
|
Inventory | 423.51 | 122.14 | 15.32 | 10.9 | 50.72 | Upgrade
|
Other Current Assets | 14.56 | 25.62 | 4.97 | 11.58 | 56.76 | Upgrade
|
Total Current Assets | 1,450 | 775.23 | 195.91 | 91.52 | 191.95 | Upgrade
|
Property, Plant & Equipment | 593.77 | 478.56 | 259.38 | 252.52 | 271.24 | Upgrade
|
Long-Term Investments | 2.23 | 2.23 | 0.01 | 0.12 | 0.13 | Upgrade
|
Goodwill | 233.47 | 233.47 | 38.41 | 38.41 | 38.35 | Upgrade
|
Other Intangible Assets | - | 0.15 | - | - | - | Upgrade
|
Long-Term Deferred Tax Assets | 13.56 | 0.38 | - | - | - | Upgrade
|
Other Long-Term Assets | 57.46 | 69.6 | 20.3 | 17.98 | 13.07 | Upgrade
|
Total Assets | 2,350 | 1,560 | 514.01 | 400.55 | 514.74 | Upgrade
|
Accounts Payable | 373.9 | 227.38 | 58.2 | 33.36 | 62.57 | Upgrade
|
Accrued Expenses | 55.3 | 54.82 | 22.03 | 10.89 | 1.36 | Upgrade
|
Short-Term Debt | 398.51 | 314.31 | 111.03 | 73.83 | 67.97 | Upgrade
|
Current Portion of Long-Term Debt | 12.16 | 19.44 | - | - | - | Upgrade
|
Current Portion of Leases | 7.93 | 11.25 | 3.57 | - | - | Upgrade
|
Current Income Taxes Payable | 6.19 | 2.01 | - | - | - | Upgrade
|
Current Unearned Revenue | 0.33 | 0.12 | - | - | - | Upgrade
|
Other Current Liabilities | 16.4 | 89.77 | - | - | 4.89 | Upgrade
|
Total Current Liabilities | 870.72 | 719.1 | 194.82 | 118.07 | 136.79 | Upgrade
|
Long-Term Debt | 665.97 | 293.7 | 67.85 | 81.54 | 69.44 | Upgrade
|
Long-Term Leases | 40.67 | 63.16 | 5.5 | - | - | Upgrade
|
Long-Term Deferred Tax Liabilities | 10.24 | 0.14 | 0.14 | 0.14 | 0.14 | Upgrade
|
Total Liabilities | 1,588 | 1,076 | 268.31 | 199.75 | 206.37 | Upgrade
|
Common Stock | 455.36 | 342.27 | 342.27 | 342.27 | 342.27 | Upgrade
|
Additional Paid-In Capital | 126.64 | 114.01 | 0.09 | - | - | Upgrade
|
Retained Earnings | 48.94 | -13.36 | -100.72 | -145.12 | -33.9 | Upgrade
|
Comprehensive Income & Other | 41.18 | 15.44 | - | 0.05 | - | Upgrade
|
Total Common Equity | 672.12 | 458.37 | 241.63 | 197.2 | 308.37 | Upgrade
|
Minority Interest | 90.54 | -67.34 | 4.06 | 3.6 | - | Upgrade
|
Shareholders' Equity | 762.66 | 483.53 | 245.7 | 200.8 | 308.37 | Upgrade
|
Total Liabilities & Equity | 2,350 | 1,560 | 514.01 | 400.55 | 514.74 | Upgrade
|
Total Debt | 1,125 | 701.86 | 187.94 | 155.36 | 137.41 | Upgrade
|
Net Cash (Debt) | -822.72 | -574.92 | -166.15 | -148.58 | -123.39 | Upgrade
|
Net Cash Per Share | -21.13 | -13.22 | -4.85 | -4.17 | -33.93 | Upgrade
|
Filing Date Shares Outstanding | 45.54 | 34.23 | 34.23 | 34.23 | 3.64 | Upgrade
|
Total Common Shares Outstanding | 45.54 | 34.23 | 34.23 | 34.23 | 3.64 | Upgrade
|
Working Capital | 579.04 | 56.13 | 1.08 | -26.55 | 55.16 | Upgrade
|
Book Value Per Share | 14.76 | 13.39 | 7.06 | 5.76 | 84.79 | Upgrade
|
Tangible Book Value | 438.65 | 224.75 | 203.22 | 158.79 | 270.02 | Upgrade
|
Tangible Book Value Per Share | 9.63 | 6.57 | 5.94 | 4.64 | 74.25 | Upgrade
|
Land | - | - | - | - | 103.75 | Upgrade
|
Machinery | - | - | - | - | 41.7 | Upgrade
|
Construction In Progress | - | - | - | - | 135.94 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.